Skip to main content
TipRanks
Go Ultimate75% OFF

Jubilant Ingrevia Ltd. (JUBLINGREA) AI Stock Analysis

3 Followers
IN:JUBLINGREA

Jubilant Ingrevia Ltd.

(NSE:JUBLINGREA)

Select Model
Rating:53Neutral
Price Target:INR 601.00â–²(2.05% Upside)
Action:reiterated
Date:08/28/26

The score is held back primarily by weak cash-flow quality and volatility despite positive operating cash flow, alongside soft technical momentum (below key moving averages with negative MACD). A manageable balance sheet and modest revenue growth provide partial support, but a high P/E and low dividend yield further limit the score.

Positive Factors
Diversified specialty portfolioJubilant Ingrevia serves multiple end markets with specialty chemicals, intermediates and life-science ingredients. This breadth can reduce reliance on any single application, support customer diversification, and provide a durable platform for growth across domestic and international markets.
Negative Factors
Weak cash conversionAlthough operating cash flow remains positive, its persistent shortfall relative to net income signals weak cash conversion. This can limit internally funded growth, reduce flexibility for capital allocation, and make reported earnings less dependable as a measure of durable financial strength.

Jubilant Ingrevia Ltd. (JUBLINGREA) vs. iShares MSCI India ETF (INDA)

-25%-20%-15%-10%-5%0%5%10%IN:JUBLINGREA-17.91%INDA-5.34%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 94.91B
Dividend Yield
0.85%
Average Volume (3M)
42.10K
Price to Earnings (P/E)
26.5
Beta (1Y)
1.02
Revenue Growth
15.41%
EPS Growth
21.76%
Country
India
Employees
2,185
Sector
General
Sector Strength
55
Industry
Chemicals - Specialty

Jubilant Ingrevia Ltd. Business Overview & Revenue Model

Company Description

Jubilant Ingrevia Limited, established in 2019 and based in Noida, India, is a global supplier of life science products and comprehensive solutions. The company's operations are divided into three core divisions: Specialty Chemicals, Nutrition & Heal...

Jubilant Ingrevia Ltd. Financial Statement Overview

Summary

Financials are mixed: revenue has returned to modest growth and leverage remains manageable, but profitability is below prior-cycle highs and gross margin has been volatile. Cash flow quality is the main weakness, with weak cash conversion versus earnings and volatile free cash flow (including prior negative years and a sharp decline in the latest year vs FY2025).

Income Statement

63Positive

Balance Sheet

72Positive

Cash Flow

49Neutral
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue48.88B43.88B41.24B41.00B47.40B49.14B
Gross Profit21.00B10.74B19.00B18.50B20.44B19.56B
EBITDA7.26B5.94B5.56B4.56B5.79B8.59B
Net Income3.51B2.78B2.51B1.83B3.07B4.77B
Balance Sheet
Total Assets59.99B54.84B50.32B47.32B42.59B37.97B
Cash, Cash Equivalents and Short-Term Investments2.42B1.90B1.15B828.36M1.08B454.69M
Total Debt8.95B7.92B7.64B7.40B4.07B2.38B
Total Liabilities26.83B23.58B21.05B19.94B15.93B13.64B
Stockholders Equity33.16B31.26B29.27B27.37B26.66B24.33B
Cash Flow
Free Cash Flow01.63B1.42B-1.38B-189.30M2.23B
Operating Cash Flow04.62B5.08B4.30B4.62B4.53B
Investing Cash Flow0-2.77B-3.93B-5.70B-4.72B-718.56M
Financing Cash Flow0-923.50M-1.29B1.44B416.00M-4.18B

Jubilant Ingrevia Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price588.90

Price Trends

50DMA622.67Negative
100DMA666.83Negative
200DMA653.38Negative

Market Momentum

MACD-10.60Negative
RSI45.30Neutral
STOCH54.04Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JUBLINGREA, the sentiment is Negative. The current price of 588.90 is below the 20-day moving average (MA) of 589.98, below the 50-day MA of 622.67, and below the 200-day MA of 653.38, indicating a bearish trend. The MACD of -10.60 indicates Negative momentum. The RSI at 45.30 is Neutral, neither overbought nor oversold. The STOCH value of 54.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:JUBLINGREA.

Jubilant Ingrevia Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:JUBLINGREA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:SYNGENEIN:SYNGENE61NeutralINR 175.21B93.81―0.29%-5.99%-60.30%
IN:CONCORDBIOIN:CONCORDBIO57NeutralINR 116.17B41.14―1.36%4.02%-12.81%
IN:PPLPHARMAIN:PPLPHARMA56NeutralINR 319.92B-152.55―0.06%9.43%-767.49%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:JUBLINGREAIN:JUBLINGREA53NeutralINR 93.80B26.49―0.85%15.41%21.76%
IN:ONESOURCEIN:ONESOURCE48NeutralINR 181.34B-10538.67――10.66%-104.59%
IN:DCALIN:DCAL43NeutralINR 20.40B29.96――-20.86%-34.51%

* General Sector Average

Performance Comparison

-40%-20%0%20%IN:JUBLINGREAIN:CONCORDBIOIN:DCALIN:PPLPHARMAIN:SYNGENEIN:ONESOURCEDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:JUBLINGREA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:JUBLINGREAJubilant Ingrevia Ltd.588.90-119.43-16.86%
IN:CONCORDBIOConcord Biotech Ltd.555.20-165.09-22.92%
IN:DCALDishman Carbogen Amcis Ltd.130.10-112.05-46.27%
IN:PPLPHARMAPiramal Pharma Limited240.3051.4527.24%
IN:SYNGENESyngene International Ltd.434.05-199.11-31.45%
IN:ONESOURCEOneSource Specialty Pharma Limited1581.35-124.50-7.30%

Jubilant Ingrevia Ltd. Corporate Events

Jubilant Ingrevia Enters Electronics Design and Manufacturing Services

Nov 8, 2026

Jubilant Ingrevia Limited is a specialty chemicals and CDMO company with manufacturing and customer-focused capabilities. Its focus includes semiconductor and electronics chemicals, alongside services for customers in advanced electronics and related...

Jubilant Ingrevia to Buy 40% Stake in Zettaone, Pushing into Electronics and Semiconductor Services

Aug 18, 2026

Jubilant Ingrevia Limited has approved a binding term sheet to acquire a 40% strategic equity stake in Zettaone Technologies India Pvt. Ltd., an integrated electronics design and manufacturing platform, for approximately ₹189.2 crore in cash. The tra...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 28, 2026